Navigation Links
FDA-Approved Sculptra@ Now Offers by Orange County Dermatologist Dr. Cheryl Effron
Date:11/10/2009

Board Certified Dermatologist and Regional Sculptra@ trainer Dr Cheryl Effron of Cosmetic Dermatology of Orange County offers Sculptra Aesthetic@ at affordable prices.

(PRWEB) November 10, 2009 -- Board Certified Dermatologist and Regional Sculptra@ trainer Dr Cheryl Effron of Cosmetic Dermatology of Orange County offers Sculptra Aesthetic@ at affordable prices.

Sculptra Aesthetic@ is a facial injectable treatment which volumizes shallow to deep facial wrinkles and folds by stimulating the growth of human collagen (which we tend to lose with age). An injectable form of poly-L-lactic-acid (PLLA), it has been used for some years for medical purposes, but has only recently been approved by the FDA for cosmetic purposes.

The effects of Sculptra Aesthetic@ are gradual and less likely than more immediate treatments to leave patients looking as though they’ve “had work done.” In addition to being gradual, the effects can last for over 2 years. Being a simple injective, Sculptra Aesthetic@ is minimally invasive, completely biocompatible, and requires no downtime. Furthermore, because a local anesthetic is already applied, treatment can be combined with facial correctors (ie. Juvaderm, Resthalyne, Radiesse, etc). In addition to this, Sculptra Aesthetic@ can be purchased at an affordable price (9 CCs for $895).

Dr. Effron was trained in Europe (where injectible poly-L-lactic-acid has been used for years) for this procedure. Also, Dr. Effron is a Board Certified Trainer for Plastic Surgeons and Dermatologists for Sculptra. Dr. Effron is also a regional trainer for this procedure, and was one of the first dermatologists in the US to obtain certification in its administration. This procedure should only be done by a Board Certified Trainer.

Cosmetic Dermatology of Orange County offices are conveniently located in Huntington Beach (a short drive from the 405 FWY) and Anaheim Hills (a short drive from the 91 FWY).

# # #

Read the full story at http://www.prweb.com/releases/2009/11/prweb3169674.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States
2. Upsher-Smith Launches New Website for Divigel(R), a Bioidentical and FDA-Approved Hormone Therapy for Moderate to Severe Hot Flashes, Including Night Sweats, Associated with Menopause
3. Introducing anuleaf AD, a New FDA-Approved Hemorrhoid Treatment
4. MultiVu Video Feed: SCIELE PHARMA ANNOUNCES AVAILABILITY OF ULESFIA(TM), FIRST AND ONLY FDA-APPROVED NON-NEUROTOXIC HEAD LICE TREATMENT
5. Coapt Systems, Inc. Launches Hydrelle(TM) a New, FDA-Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction and Greater Patient Comfort
6. Grow Back Eyelashes - Orange County Plastic Surgeon Now Helps Patients Grow Longer, Fuller Darker Eyelashes With FDA-Approved Prescription Lash Treatment, Latisse
7. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
8. Edge Health Solutions Releases edgeDMS(TM) 2.0 and edgeMD 2.0(TM), Revolutionary All-in-One Practice Management Software with FDA-Approved Advanced Visualization
9. Oregon Cosmetic Vein Center Opens in Portland, Among First on West Coast to Offer Brand New, FDA-Approved Procedures and Technologies
10. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
11. Anesiva Announces Hiring of Sales Force for FDA-Approved Product Zingo(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Los Angeles, CA (PRWEB) , ... February 21, 2017 , ... ... the available data on gastric balloons for weight loss. It found that the treatments ... the efforts of obese patients, when compared to unassisted efforts. It also noted very ...
(Date:2/20/2017)... ... ... Nancy Johnston Toll marks her debut in the publishing scene with ... the Road ” (published by Xlibris). Inspired from her personal experiences, this compendium abounds ... downs experienced by anyone going through cancer treatment and how one can be a ...
(Date:2/20/2017)... ... ... Researchers at the University of Pittsburgh School of Medicine have uncovered a ... response to a particular class of drugs, not just in patients with thyroid cancer, ... were published in Proceedings of the National Academy of Science. , “These results further ...
(Date:2/20/2017)... ... 2017 , ... Best Doctors® and IBM today announced that ... that want to help members of their workforce battling cancer. Through the Best ... suite of oncology offerings for insights on cancer treatment options, ranging from standard ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... care providers and health plan partners, announced during the 2017 Annual HIMSS ... enhancing care coordination for diabetic patients and integrating eye care into mainstream ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... FALLS, Idaho , Feb. 21, 2017  International ... has completed a private placement with certain investors for ... stock of the Company, Series C Convertible Redeemable Preferred ... accrues dividends at an annual rate of 6% and ... The Company plans to use the proceeds for operating ...
(Date:2/21/2017)... Feb. 21, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Liver Cirrhosis Drugs Price Analysis and ... Liver Cirrhosis market. The research answers the following questions: ... and their clinical attributes? How are they positioned in the Global Liver ...
(Date:2/20/2017)... Resonance Imaging (MRI) Systems Market Outlook to 2022 ... GlobalData,s ... 2022", provides key market data on the EU5 Magnetic Resonance Imaging ... dollars, volume (in units) and average prices (USD) within market segements ... The report also provides company shares and distribution shares data for ...
Breaking Medicine Technology: